A Phase 2 study of an experimental Alzheimer’s disease treatment designed to slow or prevent cognitive decline in people carrying a specific genetic mutation failed to meet its primary endpoints, the Roche Group announced on 16 June. The placebo-controlled trial was evaluating the monoclonal antibody crenezumab as a potential treatment for early-onset Alzheimer’s in people carrying the Presenilin 1 E280A mutation.
